David Chaplin

Directeur/Membre du Conseil chez Phusis Therapeutics, Inc.

Profil

David J.
Chaplin currently works at Phusis Therapeutics, Inc., as Director from 2012 and Fast BioPharma Ltd., as Non-Executive Director from 2017.
Dr. Chaplin also formerly worked at Oncotelic Therapeutics, Inc., as Executive Vice Chairman & Chief Scientific Officer from 2000 to 2011, Oncotelic Therapeutics, Inc., as Director & Chief Scientific Officer from 2018 to 2019, Rhone Poulenc Rorer, as Senior Director-Oncology from 1998 to 1999, Aston Biopharma Ltd., as Director, Smart Matrix Ltd., as Director, Xenova Group Plc, as Section Head-Cancer Biology from 1990 to 1992, Aventis Pharma SARL, as Vice President-Oncology from 1999 to 2000, and The Cancer Research Campaign, as Head-Tumor Microcirculation Group from 1992 to 1998.
Dr. Chaplin received his graduate degree from The University of Southampton, doctorate degree from the University of London, and undergraduate degree from the University of Essex.

Postes actifs de David Chaplin

Sociétés	Poste	Début
Phusis Therapeutics, Inc.	Directeur/Membre du Conseil	01/07/2012
Fast BioPharma Ltd.	Directeur/Membre du Conseil	01/01/2017

Anciens postes connus de David Chaplin

Sociétés	Poste	Fin
ONCOTELIC THERAPEUTICS, INC.	Directeur Général	12/05/2015
ONCOTELIC THERAPEUTICS, INC.	Directeur Technique/Scientifique/R&D	30/08/2011
Aventis Pharma SARL	Corporate Officer/Principal	01/01/2000
Rhone Poulenc Rorer	Corporate Officer/Principal	01/01/1999
The Cancer Research Campaign	Corporate Officer/Principal	01/01/1998